A life-sciences focused venture capital incubator / accelerator based in the Western US is looking to provide capital in the form of equity and convertible notes to seed and venture stage companies in the life science space. The firm can provide capital in the range of a few hundred thousand to $2 million or more by leveraging its groups of angel syndicates. The firm invests in companies across the United States, Europe and Australia with a preference for California based companies. The firm looks to be involved in 3 new companies per year. The VC is currently looking for companies in areas of Medical Technology / Devices, Therapeutics and Companion Diagnostics. In the Medical Device space the firm is open in terms of sector and indication and will consider firms that are in the development phase as well as those that have entered clinical trials. In the therapeutics space the firm is generally open as well however the firm is highly interested in areas of cell and gene therapy and oncology. For therapeutics the firm tends to get involved at the preclinical stage or during phase I of clinical trials. The firm is looking for confident and experienced management teams. Given the early stage investment style that the firm has, they often work with management teams that are incomplete and have primarily academic backgrounds. Part of the value that the firm looks to add is helping firms fill in the gaps in their current management.
Popular Topics
Listen to the Podcast
Top Posts
- Navigating JPM Week: A Guide to RESI’s 2026 Event Lineup
- Meet Meki Durakovic: The Hospitality Force Behind Boston’s Culinary Hotspots
- Companies to Watch in 2026
- Drug Development: What Does It Cost, and Who Has The Capital?
- Marketing Collateral for Your Fundraising Strategy
- Inomagen Therapeutics: RESI Boston June IPC Winner
- Announcement: LSN Company Database Updates
- VIDEO - Medical Device BD Experts Provide Advice to Early Stage Entrepreneurs
- Companies to Watch 2025
- Next Week’s Live Panel Schedule, Part of Digital RESI September 2020
Recent Posts
- Companies to Watch in 2026
- RESI JPM 2026 Investor Panels Announced
- Sunday Space + Two Full Days of RESI JPM
- Hot Investor Mandate: Europe-Based VC Firm With Strong Track Record Invests Up to €20M, Open to All Life Science & Healthcare Sectors
- Hot Investor Mandate: Global Pharma With Investment Subsidiary Seeks Companies Developing Novel Drugs, Open to Various Modalities
Hot Mandates
-
Hot Investor Mandate 1: Korean VC Firm with Pharma Affiliation Seeks to Invest in Early Stage Therapeutics Assets, Most Interested in Oncology and Autoimmune Disease
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
-
Hot Investor Mandate 2: Hong Kong Boutique VC Firm Invests in All Kinds of Healthcare Technologies and Most Interested in Large Disease Markets of Unmet Medical Need
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
-
Hot Investor Mandate 3: Strategic Investment Firm of Large Pharma Invests in Early and Late Stage Therapeutics & Drug-Device Combinations, Especially Interested in Orphan and Rare Diseases
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
-
Hot Investor Mandate 4: USA-Based Investment Firm Can Invest Over $10M in Innovative Medtech and Digital Health Companies Based in Texas or Southwestern USA
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
-
Hot Investor Mandate 1: Global VC Firm Headquartered in Asia Invests in All Parts of Therapeutics, Medical Devices, Diagnostics, and Digital Health
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Contact us
Archives
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 